Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-kappaB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS, RRMS or CPMS) as well as neurodegenerative diseases research[1].
Molekulargewicht:
361.83
Reinheit:
98.25
CAS Nummer:
[1214267-09-0]
Formel:
C19H12D5ClN2O3
Target-Kategorie:
Apoptosis,Isotope-Labeled Compounds,NF-kappaB
Anwendungsbeschreibung:
MCE Product type: Isotope-Labeled Compounds
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
